EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

NCT00105183 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

223

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary
Idiopathic Pulmonary Fibrosis
Cystic Fibrosis
Bronchiectasis
Pulmonary Vascular Disease

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: EZ-2053
BIOLOGICAL: EZ-2053 5mg/kg

Sponsor

Neovii Biotech